Enzon Pharmaceuticals, Inc. (ENZN)
OTCMKTS
· Delayed Price · Currency is USD
0.0855
+0.0054 (6.74%)
May 14, 2025, 9:31 AM EDT
Enzon Pharmaceuticals Revenue
Enzon Pharmaceuticals had revenue of $26.00K in the twelve months ending March 31, 2025. In the year 2024, Enzon Pharmaceuticals had annual revenue of $26.00K.
Revenue
26.00K
Revenue Growth
n/a
P/S Ratio
242.05
Revenue / Employee
26.00K
Employees
1
Market Cap
6.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 26.00K | -675.00K | -96.29% |
| Dec 31, 2021 | 701.00K | 649.00K | 1,248.08% |
| Dec 31, 2020 | 52.00K | -155.00K | -74.88% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Enzon Pharmaceuticals News
- 4 years ago - Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO - GlobeNewsWire
- 4 years ago - Enzon Pharmaceuticals Announces Results of Rights Offering - GlobeNewsWire
- 5 years ago - Enzon Pharmaceuticals Announces Key Dates for Rights Offering - GlobeNewsWire
- 5 years ago - Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting - GlobeNewsWire
- 5 years ago - Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders - GlobeNewsWire
- 5 years ago - Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value - GlobeNewsWire
- 6 years ago - Bullish On Enzon And Sesen From Different Perspectives - Seeking Alpha
- 6 years ago - Enzon Pharmaceuticals - Heads Equals Royalties, Tails Equals Cash - Seeking Alpha